OKYO Pharma (OKYO) Projected to Post Earnings on Wednesday

OKYO Pharma (NASDAQ:OKYO) is expected to be releasing its resultson Wednesday, June 3rd. Analysts expect OKYO Pharma to post earnings of ($0.08) per share for the quarter.

OKYO Pharma Stock Up 4.9%

NASDAQ:OKYO opened at $1.71 on Wednesday. OKYO Pharma has a one year low of $1.44 and a one year high of $3.35. The stock has a 50 day moving average price of $1.61 and a 200 day moving average price of $1.89.

Wall Street Analysts Forecast Growth

Several research firms recently commented on OKYO. Piper Sandler began coverage on OKYO Pharma in a report on Friday, February 20th. They issued an “overweight” rating and a $7.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of OKYO Pharma in a research note on Tuesday, April 21st. Finally, HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of OKYO Pharma in a research note on Thursday, January 29th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $6.33.

Institutional Investors Weigh In On OKYO Pharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC increased its stake in OKYO Pharma by 235.0% during the fourth quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock worth $286,000 after acquiring an additional 96,800 shares during the last quarter. XTX Topco Ltd acquired a new stake in OKYO Pharma during the fourth quarter worth $36,000. Finally, Citadel Advisors LLC acquired a new stake in OKYO Pharma during the third quarter worth $31,000. Institutional investors and hedge funds own 2.97% of the company’s stock.

OKYO Pharma Company Profile

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.